United States - English - NLM (National Library of Medicine)

dna labs, inc. - selenicereus grandiflorus whole (unii: x8h7hs7mrm) (selenicereus grandiflorus whole - unii:x8h7hs7mrm), crataegus laevigata whole (unii: efx9g567mj) (crataegus laevigata whole - unii:efx9g567mj), dibasic potassium phosphate (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw), valeriana officinalis whole (unii: fp6o7f1x9r) (valeriana officinalis whole - unii:fp6o7f1x9r), spigelia anthelmia (unii: wyt05213ge) (spigelia anthelmia - un - support for the heart.

United States - English - NLM (National Library of Medicine)

dna labs, inc. - barium chloride dihydrate (unii: el5gj3u77e) (barium cation - unii:v645272hln), conium maculatum whole (unii: 79g218zmb3) (conium maculatum whole - unii:79g218zmb3), arnica montana (unii: o80ty208zw) (arnica montana - unii:o80ty208zw, arnica montana root - unii:mue8y11327), phosphoric acid (unii: e4ga8884nn) (phosphoric acid - unii:e4ga8884nn), dibasic potassium phosphate (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152), ferrosoferric phosphate (unii: 91gqh8i5f7) (ferrosoferric phosphate - unii:91gqh8i5f7), pork brain (unii: 466251j72g) (pork brain - unii:466251j72g) - support for the brain, poor memory.

United States - English - NLM (National Library of Medicine)

dna labs, inc. - lobelia inflata (unii: 9pp1t3tc5u) (lobelia inflata - unii:9pp1t3tc5u), strychnos ignatii seed (unii: 1nm3m2487k) (strychnos ignatii seed - unii:1nm3m2487k), avena sativa flowering top (unii: ma9cqj3f7f) (avena sativa flowering top - unii:ma9cqj3f7f), dibasic potassium phosphate (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152), selenicereus grandiflorus stem (unii: 7114sv0myk) (selenicereus grandiflorus stem - unii:7114sv0myk), glutamine (unii: 0rh81l854j) (glut - alcohol, nicotine and morphine addiction.

United States - English - NLM (National Library of Medicine)

hyland's inc. - magnesium phosphate, dibasic trihydrate (unii: hf539g9l3q) (magnesium cation - unii:t6v3lhy838), toxicodendron pubescens leaf (unii: 6io182rp7a) (toxicodendron pubescens leaf - unii:6io182rp7a), dibasic potassium phosphate (unii: ci71s98n1z) (potassium cation - unii:295o53k152), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), hypericum perforatum (unii: xk4iux8mnb) (hypericum perforatum - unii:xk4iux8mnb) - pain relief ■ temporarily relieves: ■ minor joint pain ■ headache ■ muscle pain ■ backache ■ muscle cramps ■ pain in neck or shoulders

Philippines - English - FDA (Food And Drug Administration)

zoetis philippines inc.; distributor: zoetis philippines inc. - sterile phosphate buffer solution (vet.) - solution for injection - formulation: each 1,000 ml contains: sucrose.........50 g nz amine as........14 g dibasic potassium phosphate...1.13 g disodium edta........100 mg phenol red.........10 mg water for injection (wfi).. .1,000 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

active elements pty ltd - dibasic potassium phosphate, quantity: 5 microgram; dibasic potassium phosphate, quantity: 60 mg (equivalent: potassium, qty 26.94 mg); magnesium phosphate pentahydrate, quantity: 100 mg (equivalent: magnesium, qty 20.66 mg); magnesium phosphate pentahydrate, quantity: 5 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; acacia; inulin; soy polysaccharide; magnesium stearate; riboflavine sodium phosphate; tapioca starch; colloidal anhydrous silica; calcium phosphate - traditionally used in homoeopathic medicine to relieve weariness/tiredness/fatigue/feeling of weakness ; traditionally used in homoeopathic medicine to helps temporarily relieve light sensitivity ; maintain/support general health and wellbeing ; traditionally used in homoeopathic medicine to decrease/reduce halitosis/bad breath ; traditionally used in homoeopathic medicine to decrease/reduce/relieve colic (wind/gas pain) ; traditionally used in homoeopathic medicine to decrease/reduce/relieve flatulence/carminative ; traditionally used in homoeopathic medicine to decrease/reduce/relieve abdominal cramping ; traditionally used in homoeopathic medicine to helps reduce occurrence of abdominal spasm ; traditionally used in homoeopathic medicine to decrease/reduce/relieve symptoms of nervous indigestion ; traditionally used in homoeopathic medicine to decrease/reduce/relieve muscle cramps ; traditionally used in homoeopathic medicine to helps decrease/reduce/relieve mild muscle spasms/twitches ; traditionally used in homoeopathic medicine to relieve irritability ; traditionally used in homoeopathic medicine to soothe/calm nerves ; traditionally used in homoeopathic medicine to decrease/reduce/relieve symptoms of stress ; traditionally used in homoeopathic medicine to decrease/reduce/relieve nervous tension/unrest ; traditionally used in homoeopathic medicine to decrease/reduce/relieve symptoms of mild anxiety ; traditionally used in homoeopathic medicine to decrease/reduce mental/cognitive fatigue ; traditionally used in homoeopathic medicine to decrease/reduce/relieve headache symptoms ; traditionally used in homoeopathic medicine to decrease/reduce/relieve mild migraine symptoms ; traditionally used in homoeopathic medicine to helps decrease/reduce/relieve symptoms of sensitivity to light/sound associated with mild migraine ; traditionally used in homoeopathic medicine to helps decrease/reduce/relieve symptoms of mild tension headache ; traditionally used in homoeopathic medicine to decrease/reduce/relieve mild nerve pain/neuralgia ; traditionally used in homoeopathic medicine to decrease/reduce/relieve menstrual spasms/cramps ; traditionally used in homoeopathic medicine to decrease/reduce/relieve menstruation pain/dysmenorrhoea

Australia - English - Department of Health (Therapeutic Goods Administration)

martin & pleasance pty ltd - dibasic potassium phosphate trihydrate, quantity: 48.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; calcium hydrogen phosphate dihydrate; magnesium stearate - schuessler tissue salts nerve nutrient kali phos is a homoeopathic preparation that has traditionally been used for the temporary relief of nervous tension, irritability, depression and tension headaches.

Australia - English - Department of Health (Therapeutic Goods Administration)

martin & pleasance pty ltd - potassium chloride, quantity: 4.85 mg; calcium hydrogen phosphate dihydrate, quantity: 4.85 mg; magnesium phosphate pentahydrate, quantity: 4.85 mg; dibasic potassium phosphate trihydrate, quantity: 4.85 mg - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; lactose monohydrate - for the temporary relief of menstrual pain, stomach cramps, bloating and headaches.

United States - English - NLM (National Library of Medicine)

seroyal usa - potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphate, dibasic 1 [hp_x] - indications for the temporary relief of fatigue, muscle aches and pains indications for the temporary relief of fatigue, muscle aches and pains directions adults: take five granules three times daily or as recommended by your healthcare practitioner. children: take three granules and follow adult directions.

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals,inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic, anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - monobasic sodium phosphate and dibasic sodium phosphate tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in the following conditions: -   history of acute phosphate nephropathy [see warnings and precautions (5.1)] -   gastrointestinal (gi) obstruction [see warnings and precautions (5.7)] -   gastric bypass or stapling surgery -   bowel perforation -   toxic colitis -   toxic megacolon -   hypersensitivity to sodium phosphate salts or any component of monobasic sodium phosphate and dibasic sodium phosphate tablets[see warnings and precautions (5.7)]. risk summary there are no available data on sodium phosphate use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. animal reproduction studies have not been conducted with sodium phosphate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data available to assess the presence of sodium phosphate in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of monobasic sodium phosphate and dibasic sodium phosphate tablets to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for monobasic sodium phosphate and dibasic sodium phosphate tablets and any potential adverse effects on the breastfed child from monobasic sodium phosphate and dibasic sodium phosphate tablets or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. of the 599 patients in clinical trials receiving at least 48 grams of monobasic sodium phosphate and dibasic sodium phosphate tablets, 134 (22%) were 65 years of age or older, while 27 (5%) were 75 years of age or older. no overall differences in safety or effectiveness were observed between geriatric patients and younger patients. however, the mean phosphate levels in geriatric patients were greater than the phosphate levels in younger patients after monobasic sodium phosphate and dibasic sodium phosphate tablets administration. the mean colonoscopy-day phosphate levels in patients 18-64, 65-74, and ≥ 75 years old who received the recommended monobasic sodium phosphate and dibasic sodium phosphate tablets dosage regimen in study 1were 7.0, 7.3, and 8.0 mg/dl, respectively. after monobasic sodium phosphate and dibasic sodium phosphate tablets administration, the mean phosphate levels in patients 18-64, 65-74, and ≥ 75 years old were 7.4, 7.9, and 8.0 mg/dl, respectively. greater sensitivity of some older individuals cannot be ruled out; therefore, use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in geriatric patients. advise geriatric patients to adequately hydrate before, during, and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets. sodium phosphate is known to be substantially excreted by the kidney, and the risk of adverse reactions with sodium phosphate may be greater in patients with impaired renal function. since geriatric patients are more likely to have impaired renal function, consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1)]. sodium phosphate is substantially excreted by the kidney. use monobasic sodium phosphate and dibasic sodium phosphate tablets with caution in patients with severe renal impairment (creatinine clearance less than 30 ml/min) or patients taking concomitant medications that may affect renal function. these patients may be at risk for renal injury. advise these patients of the importance of adequate hydration before, during and after the use of monobasic sodium phosphate and dibasic sodium phosphate tablets, and consider performing baseline and post-colonoscopy labs (phosphate, calcium, potassium, sodium, creatinine, and bun) in these patients [see warnings and precautions (5.1), drug interactions (7.1)] .